Linking vascular disorders and Alzheimer's disease: Potential involvement of BACE1

Neurobiology of Aging

Volumn 30, Issue 10, 2009, Pages 1535-1544

  Cole, Sarah L ^a   Vassar, Robert ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Alzheimers disease; BACE1; Beta amyloid peptide; Cardiovascular; Cerebrovascular; Hypoperfusion

Indexed keywords

AMYLOID BETA PROTEIN; BETA SECRETASE; BETA SITE APP CLEAVING ENZYME 1; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BRAIN ATHEROSCLEROSIS; BRAIN BLOOD FLOW; BRAIN HYPOXIA; BRAIN MITOCHONDRION; BRAIN PERFUSION; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; ENZYME ACTIVITY; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; UPREGULATION; VASCULAR DISEASE;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ENDOPEPTIDASES; BRAIN; CEREBROVASCULAR DISORDERS; DISEASE MODELS, ANIMAL; HUMANS; MICE;

EID: 69249212436     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2007.12.012     Document Type: Review

References (120)

1. Basi G., Frigon N., Barbour R., Doan T., Gordon G., McConlogue L., Sinha S., and Zeller M. Antagonistic effects of beta-site amyloid precursor protein-cleaving enzymes 1 and 2 on beta-amyloid peptide production in cells. J. Biol. Chem. 278 (2003) 31512-31520
2. Beach T.G., Wilson J.R., Sue L.I., Newell A., Poston M., Cisneros R., Pandya Y., Esh C., Connor D.J., Sabbagh M., Walker D.G., and Roher A.E. Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol. (Berl.) 113 (2007) 13-21
3. Bennett B.D., Babu-Khan S., Loeloff R., Louis J.-C., Curran E., Citron M., and Vassar R. Expression analysis of BACE2 in brain and peripheral tissues. J. Biol. Chem. 275 (2000) 20647-20651
4. Blasko I., Beer R., Bigl M., Apelt J., Franz G., Rudzki D., Ransmayr G., Kampfl A., and Schliebs R. Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer's disease beta-secretase (BACE-1). J. Neural Transm. 111 (2004) 523-536
5. Bourne K.Z., Ferrari D.C., Lange-Dohna C., Rossner S., Wood T.G., and Perez-Polo J.R. Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides. J. Neurosci. Res. 85 (2007) 1194-1204
6. Buxbaum J.D., Liu K.N., Luo Y., Slack J.L., Stocking K.L., Peschon J.J., Johnson R.S., Castner B.J., Cerretti D.P., and Black R.A. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J. Biol. Chem. 273 (1998) 27765-27767
7. Chandrasekaran, Hatanpaa, Brady D.R., and Rapoport S.I. Evidence for physiological down-regulation of brain oxidative phosphorylation in Alzheimer's disease. Exp. Neurol. 142 (1996) 80-88
8. Christie R., Yamada M., Moskowitz M., and Hyman B. Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy. Am. J. Pathol. 158 (2001) 1065-1071
9. Cole S.L., and Vassar R. The Alzheimer's disease β-secretase enzyme, BACE1. Mol. Neuro. 2 (2007) 22
10. Coma M., Guix F.X., Ill-Raga G., Uribesalgo I., Alameda F., Valverde M.A., and Munoz F.J. Oxidative stress triggers the amyloidogenic pathway in human vascular smooth muscle cells. Neurobiol. Aging 29 7 (2008) 969-980
11. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., and Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 (1993) 921-923
12. Crawford F., Suo Z., Fang C., and Mullan M. Characteristics of the in vitro vasoactivity of beta-amyloid peptides. Exp. Neurol. 150 (1998) 159-168
13. de la Torre J.C. Critical threshold cerebral hypoperfusion causes Alzheimer's disease?. Acta Neuropathol. (Berl.) 98 (1999) 1-8
14. de la Torre J.C. How do heart disease and stroke become risk factors for Alzheimer's disease?. Neurol. Res. 28 (2006) 637-644
15. De Pietri Tonelli D., Mihailovich M., Di Cesare A., Codazzi F., Grohovaz F., and Zacchetti D. Translational regulation of BACE-1 expression in neuronal and non-neuronal cells. Nucleic Acids Res. 32 (2004) 1808-1817
16. Dewachter I., Reverse D., Caluwaerts N., Ris L., Kuiperi C., Van den Haute C., Spittaels K., Umans L., Serneels L., Thiry E., Moechars D., Mercken M., Godaux E., and Van Leuven F. Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice. J. Neurosci. 22 (2002) 3445-3453
17. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P.J., and Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6 (2007) 734-746
18. Erkinjuntti T., Sawada T., and Whitehouse P.J. The Osaka Conference on Vascular Dementia 1998. Alzheimer Dis. Assoc. Disord. 13 Suppl. 3 (1999) S1-S3
19. Fukumoto H., Cheung B.S., Hyman B.T., and Irizarry M.C. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch. Neurol. 59 (2002) 1381-1389
20. Goate A., Chartier-Harlin M.-C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L., Mant R., Newton P., Rooke K., Roques P., Talbot C., Pericak-Vance M., Roses A., Williamson R., Rossor M., Owen M., and Hardy J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349 (1991) 704-706
21. Golde T.E., Dickson D., and Hutton M. Filling the gaps in the abeta cascade hypothesis of Alzheimer's disease. Curr. Alzheimer Res. 3 (2006) 421-430
22. Harada H., Tamaoka A., Ishii K., Shoji S., Kametaka S., Kametani F., Saito Y., and Murayama S. Beta-site APP cleaving enzyme 1 (BACE1) is increased in remaining neurons in Alzheimer's disease brains. Neurosci. Res. 54 (2006) 24-29
23. Hardy J. A hundred years of Alzheimer's disease research. Neuron 52 (2006) 3-13
24. Hebert R., and Brayne C. Epidemiology of vascular dementia. Neuroepidemiology 14 (1995) 240-257
25. Herms J., Anliker B., Heber S., Ring S., Fuhrmann M., Kretzschmar H., Sisodia S., and Muller U. Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members. EMBO J. 23 (2004) 4106-4115
26. Holsinger R.M., McLean C.A., Beyreuther K., Masters C.L., and Evin G. Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann. Neurol. 51 (2002) 783-786
27. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., and Cole G. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274 (1996) 99-103
28. Hu X., Hicks C.W., He W., Wong P., Macklin W.B., Trapp B.D., and Yan R. Bace1 modulates myelination in the central and peripheral nervous system. Nat. Neurosci. 9 (2006) 1520-1525
29. Huang L.E., Willmore W.G., Gu J., Goldberg M.A., and Bunn H.F. Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide. Implications for oxygen sensing and signalling. J. Biol. Chem. 274 (1999) 9038-9044
30. Huang L.S., Sun G., Cobessi D., Wang A.C., Shen J.T., Tung E.Y., Anderson V.E., and Berry E.A. 3-nitropropionic acid is a suicide inhibitor of mitochondrial respiration that, upon oxidative by complex II, forms a covalent adduct with a catalytic base arginine in the active site of the enzyme. J. Biol. Chem. 281 (2006) 5965-5972
31. Hyman B.T., Strickland D., and Rebeck G.W. Role of the low-density lipoprotein receptor-related protein in beta-amyloid metabolism and Alzheimer disease. Arch. Neurol. 57 (2000) 646-650
32. Iadecola C. Atherosclerosis and neurodegeneration: unexpected conspirators in Alzheimer's dementia. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1951-1953
33. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat. Rev. Neurosci. 5 (2004) 347-360
34. Johnson K.A., Jones K., Holman B.L., Becker J.A., Spiers P.A., Satlin A., and Albert M.S. Preclinical prediction of Alzheimer's disease using SPECT. Neurology 50 (1998) 1563-1571
35. Kalaria R.N., and Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis. Assoc. Disord. 13 Suppl. 3 (1999) S115-S123
36. Kalback W., Esh C., Castano E.M., Rahman A., Kokjohn T., Luehrs D.C., Sue L., Cisneros R., Gerber F., Richardson C., Bohrmann B., Walker D.G., Beach T.G., and Roher A.E. Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. Neurol. Res. 26 (2004) 525-539
37. Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., Sisodia S., and Malinow R. APP processing and synaptic function. Neuron 37 (2003) 925-937
38. Kim D.Y., Carey B.W., Wang H., Ingano L.A., Binshtok A.M., Wertz M.H., Pettingell W.H., He P., Lee V.M., Woolf C.J., and Kovacs D.M. BACE1 regulates voltage-gated sodium channels and neuronal activity. Nat. Cell Biol. 9 (2007) 755-764
39. Kitazume S., Nakagawa K., Oka R., Tachida Y., Ogawa K., Luo Y., Citron M., Shitara H., Taya C., Yonekawa H., Paulson J.C., Miyoshi E., Taniguchi N., and Hashimoto Y. In vivo cleavage of alpha2,6-sialyltransferase by Alzheimer beta-secretase. J. Biol. Chem. 280 (2005) 8589-8595
40. Laird F.M., Cai H., Savonenko A.V., Farah M.H., He K., Melnikova T., Wen H., Chiang H.C., Xu G., Koliatsos V.E., Borchelt D.R., Price D.L., Lee H.K., and Wong P.C. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J. Neurosci. 25 (2005) 11693-11709
41. Lammich S., Schobel S., Zimmer A.K., Lichtenthaler S.F., and Haass C. Expression of the Alzheimer protease BACE1 is suppressed via its 5′-untranslated region. EMBO Rep. 5 (2004) 620-625
42. Lammich S., Kojro E., Postina R., Gilbert S., Pfeiffer R., Jasionowski M., Haass C., and Fahrenholz F. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 3922-3927
43. Levitan D., and Greenwald I. Facilitation of lin-12 -mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene. Nature 377 (1995) 351-354
44. Levy-Lahad E., Wasco W., Poorkaj P., Romano D.M., Oshima J., Pettingell W.H., Yu C.E., Jondro P.D., Schmidt S.D., Wang K., Crowley A.C., Fu Y.H., Guenette S.Y., Galas D., Nemens E., Wijsman E.M., Bird T.D., Schellenberg G.D., and Tanzi R.E. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269 (1995) 973-977
45. Li Q., and Sudhof T.C. Cleavage of amyloid-beta precursor protein and amyloid-beta precursor-like protein by BACE 1. J. Biol. Chem. 279 (2004) 10542-10550
46. Li R., Lindholm K., Yang L.B., Yue X., Citron M., Yan R., Beach T., Sue L., Sabbagh M., Cai H., Wong P., Price D., and Shen Y. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 3632-3637
47. Lichtenthaler S.F., Dominguez D.I., Westmeyer G.G., Reiss K., Haass C., Saftig P., De Strooper B., and Seed B. The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J. Biol. Chem. 278 (2003) 48713-48719
48. Lindholm T., Cullheim S., Deckner M., Carlstedt T., and Risling M. Expression of neuregulin and ErbB3 and ErbB4 after a traumatic lesion in the ventral funiculus of the spinal cord and in the intact primary olfactory system. Exp. Brain Res. 142 (2002) 81-90
49. Maalikjy Akkawi N., Borroni B., Agosti C., Magoni M., Broli M., Pezzini A., and Padovani A. Volume cerebral blood flow reduction in pre-clinical stage of Alzheimer disease: evidence from an ultrasonographic study. J. Neurol. 252 (2005) 559-563
50. Madamanchi N.R., and Runge M.S. Mitochondrial dysfunction in atherosclerosis. Circ. Res. 100 (2007) 460-473
51. Mahley R.W., and Hall S.C. Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet 01 (2000) 507-537
52. Marcinkiewicz M., and Seidah N.G. Coordinated expression of β-amyloid precursor protein and the putative β-secretase BACE and α-secretase ADAM10 in mouse and human brain. J. Neurochem. 75 (2000) 2133-2143
53. Matsuda H. Cerebral blood flow and metabolic abnormalities in Alzheimer's disease. Ann. Nucl. Med. 15 (2001) 85-92
54. McConlogue L., Buttini M., Anderson J.P., Brigham E.F., Chen K.S., Freedman S.B., Games D., Johnson-Wood K., Lee M., Zeller M., Liu W., Motter R., and Sinha S. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. J. Biol. Chem. 282 (2007) 26326-26334
55. Meyer J.S., Rauch G., Rauch R.A., and Haque A. Risk factors for cerebral hypoperfusion, mild cognitive impairment, and dementia. Neurobiol. Aging 21 (2000) 161-169
56. Mielke M.M., Rosenberg P.B., Tschanz J., Cook L., Corcoran C., Hayden K.M., Norton M., Rabins P.V., Green R.C., Welsh-Bohmer K.A., Breitner J.C., Munger R., and Lyketsos C.G. Vascular factors predict rate of progression in Alzheimer disease. Neurology 69 (2007) 1850-1858
57. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging 32 (2005) 486-510
58. Mosconi L., Perani D., Sorbi S., Herholz K., Nacmias B., Holthoff V., Salmon E., Baron J.C., De Cristofaro M.T., Padovani A., Borroni B., Franceschi M., Bracco L., and Pupi A. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 63 (2004) 2332-2340
59. Niwa K., Younkin L., Ebeling C., Turner S.K., Westaway D., Younkin S., Ashe K.H., Carlson G.A., and Iadecola C. Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 9735-9740
60. Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., Berry R., and Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26 (2006) 10129-10140
61. Ohno M., Chang L., Tseng W., Oakley H., Citron M., Klein W.L., Vassar R., and Disterhoft J.F. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. Eur. J. Neurosci. 23 (2006) 251-260
62. Ohno M., Cole S.L., Yasvoina M., Zhao J., Citron M., Berry R., Disterhoft J.F., and Vassar R. BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. Neurobiol. Dis. 26 (2007) 134-145
63. Ohno M., Sametsky E.A., Younkin L.H., Oakley H., Younkin S.G., Citron M., Vassar R., and Disterhoft J.F. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a Mouse Model of Alzheimer's Disease. Neuron 41 (2004) 27-33
64. Pastorino L., Ikin A.F., Lamprianou S., Vacaresse N., Revelli J.P., Platt K., Paganetti P., Mathews P.M., Harroch S., and Buxbaum J.D. BACE (beta-secretase) modulates the processing of APLP2 in vivo. Mol. Cell Neurosci. 25 (2004) 642-649
65. Pendlebury W.W., and Solomon P.R. Alzheimer's disease. Clin. Symp. 48 (1996) 2-32
66. Petrovitch H., Ross G.W., Steinhorn S.C., Abbott R.D., Markesbery W., Davis D., Nelson J., Hardman J., Masaki K., Vogt M.R., Launer L., and White L.R. AD lesions and infarcts in demented and non-demented Japanese-American men. Ann. Neurol. 57 (2005) 98-103
67. Plant L.D., Webster N.J., Boyle J.P., Ramsden M., Freir D.B., Peers C., and Pearson H.A. Amyloid beta peptide as a physiological modulator of neuronal 'A'-type K+ current. Neurobiol. Aging 27 (2006) 1673-1683
68. Rapoport S.I. In vivo PET imaging and postmortem studies suggest potentially reversible and irreversible stages of brain metabolic failure in Alzheimer's disease. Eur. Arch. Psychiatry Clin. Neurosci. 249 Suppl. 3 (1999) 46-55
69. Reiman E.M., Caselli R.J., Yun L.S., Chen K., Bandy D., Minoshima S., Thibodeau S.N., and Osborne D. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N. Engl. J. Med. 334 (1996) 752-758
70. Riekse R.G., Leverenz J.B., McCormick W., Bowen J.D., Teri L., Nochlin D., Simpson K., Eugenio C., Larson E.B., and Tsuang D. Effect of vascular lesions on cognition in Alzheimer's disease: a community-based study. J. Am. Geriatr. Soc. 52 (2004) 1442-1448
71. Rogers G.W., Edelman Jr. G.M., and Mauro V.P. Differential utilization of upstream AUGs in the beta-secretase mRNA suggests that a shunting mechanism regulates translation. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 2794-2799
72. Roher A.E., Esh C., Kokjohn T.A., Kalback W., Luehrs D.C., Seward J.D., Sue L.I., and Beach T.G. Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 2055-2062
73. Roman G.C. Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention. Med. Clin. North Am. 86 (2002) 477-499
74. Roman G.C., Tatemichi T.K., Erkinjuntti T., Cummings J.L., Masdeu J.C., Garcia J.H., Amaducci L., Orgogozo J.M., Brun A., Hofman A., Moody D.M., O'Brien M.D., Yamaguchi T., Grafman J., Drayer B.P., Bennett D.A., Fisher M., Ogata J., Kokmen E., Bermejo F., Wolf P.A., Gorelick P.B., Bick K.L., Pajeau A.K., Bell M.A., DeCarli C., Culebras A., Korczyn A.D., Bogousslavsky J., Hartmann A., and Scheinberg P. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43 (1993) 250-260
75. Rosenberg R.N. Explaining the cause of the amyloid burden in Alzheimer disease. Arch. Neurol. 59 (2002) 1367-1368
76. Rossner S., Sastre M., Bourne K., and Lichtenthaler S.F. Transcriptional and translational regulation of BACE1 expression-implications for Alzheimer's disease. Prog. Neurobiol. 79 (2006) 95-111
77. Rovelet-Lecrux A., Hannequin D., Raux G., Le Meur N., Laquerriere A., Vital A., Dumanchin C., Feuillette S., Brice A., Vercelletto M., Dubas F., Frebourg T., and Campion D. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 38 (2006) 24-26
78. Ruitenberg A., den Heijer T., Bakker S.L., van Swieten J.C., Koudstaal P.J., Hofman A., and Breteler M.M. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann. Neurol. 57 (2005) 789-794
79. Sato J.-I., and Kuroda Y. Amyloid precursor protein β-secretase (BACE) mRNA expression in human neural cell lines following induction of neuronal differentiation and exposure to cytokines and growth factors. Neuropathology 20 (2000) 289-296
80. Sayre L.M., Zelasko D.A., Harris P.L., Perry G., Salomon R.G., and Smith M.A. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 68 (1997) 2092-2097
81. Schellenberg G.D., Bird T.D., Wijsman E.M., Orr H.T., Anderson L., Nemens E., White J.A., Bonnycastle L., Weber J.L., Alonso M.E., Potter H., Heston L.H., and Martin G.M. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 258 (1992) 668-671
82. Schneider J.A., Arvanitakis Z., Bang W., and Bennett D.A. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69 (2007) 2197-2204
83. Schneider J.A., Boyle P.A., Arvanitakis Z., Bienias J.L., and Bennett D.A. Subcortical infarcts, Alzheimer's disease pathology, and memory function in older persons. Ann. Neurol. 62 (2007) 59-66
84. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81 (2001) 741-766
85. Sharp F.R., and Bernaudin M. HIF1 and oxygen sensing in the brain. Nat. Rev. Neurosci. 5 (2004) 437-448
86. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., Yagi T., Matsuno-Yagi A., and Greenamyre J.T. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 23 (2003) 10756-10764
87. Shin H.K., Jones P.B., Garcia-Alloza M., Borrelli L., Greenberg S.M., Bacskai B.J., Frosch M.P., Hyman B.T., Moskowitz M.A., and Ayata C. Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. Brain 130 (2007) 2310-2319
88. Silvestrini M., Pasqualetti P., Baruffaldi R., Bartolini M., Handouk Y., Matteis M., Moffa F., Provinciali L., and Vernieri F. Cerebrovascular reactivity and cognitive decline in patients with Alzheimer disease. Stroke 37 (2006) 1010-1015
89. Small G.W., Ercoli L.M., Silverman D.H., Huang S.C., Komo S., Bookheimer S.Y., Lavretsky H., Miller K., Siddarth P., Rasgon N.L., Mazziotta J.C., Saxena S., Wu H.M., Mega M.S., Cummings J.L., Saunders A.M., Pericak-Vance M.A., Roses A.D., Barrio J.R., and Phelps M.E. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 6037-6042
90. Snowdon D.A., Greiner L.H., Mortimer J.A., Riley K.P., Greiner P.A., and Markesbery W.R. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. Jama 277 (1997) 813-817
91. Sorrentino G., and Bonavita V. Neurondegeneration and Alzheimer's disease: the lesson from tauopathies. Neurol. Sci. 28 (2007) 63-71
92. Song I.U., Kim J.S., Kim Y.I., Eah K.Y., and Lee K.S. Clinical significance of silent cerebral infarctions in patients with Alzheimer disease. Cogn. Behav. Neurol. 20 (2007) 93-98
93. St. George-Hyslop P.H., Haines J.L., Farrer L.A., Polinsky R., Van Broeckhoven C., Goate A., Crapper McLachlan D.R., Orr H., Bruni A.C., Sorbi S., Rainero I., Foncin J.-F., Pollen D., Cantu J.-M., Tupler R., Voskresenskaya N., Mayeux R., Growdon J., Fried V.A., Myers R.H., Nee L., Backhovens H., Martin J.-J., Rossor M., Owen M.J., Mullan M., Percy M.E., Karlinsky H., Rich S., Heston L., Montesi M., Mortilla M., Nacmias N., Gusella J.F., and Hardy J.A. Genetic linkage studies suggest that Alzheimer's disease is not a single homogeneous disorder. Nature 347 (1990) 194-197
94. Sun X., He G., Qing H., Zhou W., Dobie F., Cai F., Staufenbiel M., Huang L.E., and Song W. Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 18727-18732
95. Tamagno E., Bardini P., Guglielmotto M., Danni O., and Tabaton M. The various aggregation states of beta-amyloid 1-42 mediate different effects on oxidative stress, neurodegeneration, and BACE-1 expression. Free Radic. Biol. Med. 41 (2006) 202-212
96. Tamagno E., Bardini P., Obbili A., Vitali A., Borghi R., Zaccheo D., Pronzato M.A., Danni O., Smith M.A., Perry G., and Tabaton M. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol. Dis. 10 (2002) 279-288
97. Tamagno E., Parola M., Bardini P., Piccini A., Borghi R., Guglielmotto M., Santoro G., Davit A., Danni O., Smith M.A., Perry G., and Tabaton M. Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J. Neurochem. 92 (2005) 628-636
98. Tesco G., Koh Y.H., Kang E.L., Cameron A.N., Das S., Sena-Esteves M., Hiltunen M., Yang S.H., Zhong Z., Shen Y., Simpkins J.W., and Tanzi R.E. Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron 54 (2007) 721-737
99. Thomas T., Thomas G., McLendon C., Sutton T., and Mullan M. beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380 (1996) 168-171
100. Tong Y., Zhou W., Fung V., Christensen M.A., Qing H., Sun X., and Song W. Oxidative stress potentiates BACE1 gene expression and Abeta generation. J. Neural Transm. 112 (2005) 455-469
101. Tyler S.J., Dawbarn D., Wilcock G.K., and Allen S.J. alpha- and beta-secretase: profound changes in Alzheimer's disease. Biochem. Biophys. Res. Commun. 299 (2002) 373-376
102. Uryu K., Laurer H., McIntosh T., Pratico D., Martinez D., Leight S., Lee V.M., and Trojanowski J.Q. Repetitive mild brain trauma accelerates Abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis. J. Neurosci. 22 (2002) 446-454
103. Vassar R. BACE1: the beta-secretase enzyme in Alzheimer's disease. J. Mol. Neurosci. 23 (2004) 105-114
104. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Loeloff R., Luo Y., Fisher S., Fuller J., Edenson S., Lile J., Jarosinski M.A., Biere A.L., Curran E., Burgess T., Louis J.-C., Collins F., Treanor J., Rogers G., and Citron M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286 (1999) 735-741
105. Velliquette R.A., O'Connor T., and Vassar R. Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. J. Neurosci. 25 (2005) 10874-10883
106. von Arnim C.A., Kinoshita A., Peltan I.D., Tangredi M.M., Herl L., Lee B.M., Spoelgen R., Hshieh T.T., Ranganathan S., Battey F.D., Liu C.X., Bacskai B.J., Sever S., Irizarry M.C., Strickland D.K., and Hyman B.T. The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J. Biol. Chem. 280 (2005) 17777-17785
107. Wang P., Yang G., Mosier D.R., Chang P., Zaidi T., Gong Y.D., Zhao N.M., Dominguez B., Lee K.F., Gan W.B., and Zheng H. Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-Like protein 2. J. Neurosci. 25 (2005) 1219-1225
108. Wen Y., Onyewuchi O., Yang S., Liu R., and Simpkins J.W. Increased beta-secretase activity and expression in rats following transient cerebral ischemia. Brain Res. 1009 (2004) 1-8
109. Willem M., Garratt A.N., Novak B., Citron M., Kaufmann S., Rittger A., DeStrooper B., Saftig P., Birchmeier C., and Haass C. Control of peripheral nerve myelination by the beta-secretase BACE1. Science 314 (2006) 664-666
110. Williams T.I., Lynn B.C., Markesbery W.R., and Lovell M.A. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiol. Aging 27 (2006) 1094-1099
111. Wong H.K., Sakurai T., Oyama F., Kaneko K., Wada K., Miyazaki H., Kurosawa M., De Strooper B., Saftig P., and Nukina N. Beta subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-secretase. J. Biol. Chem. 280 (2005) 23009-23017
112. Wong P.C., Zheng H., Chen H., Becher M.W., Sirinathsinghji D.J., Trumbauer M.E., Chen H.Y., Price D.L., Van der Ploeg L.H., and Sisodia S.S. Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature 387 (1997) 288-292
113. Xia X., Qian S., Soriano S., Wu Y., Fletcher A.M., Wang X.J., Koo E.H., Wu X., and Zheng H. Loss of presenilin 1 is associated with enhanced beta-catenin signaling and skin tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 10863-10868
114. Xiong K., Cai H., Luo X.G., Struble R.G., Clough R.W., and Yan X.X. Mitochondrial respiratory inhibition and oxidative stress elevate beta-secretase (BACE1) proteins and activity in vivo in the rat retina. Exp. Brain Res. 181 (2007) 435-446
115. Yan R., Munzner J.B., Shuck M.E., and Bienkowski M.J. BACE2 functions as an alternative alpha-secretase in cells. J. Biol. Chem. 276 (2001) 34019-34027
116. Yan X.X., Xiong K., Luo X.G., Struble R.G., and Clough R.W. Beta-secretase expression in normal and functionally deprived rat olfactory bulbs: inverse correlation with oxidative metabolic activity. J. Comp. Neurol. 501 (2007) 52-69
117. Yang L.B., Lindholm K., Yan R., Citron M., Xia W., Yang X.L., Beach T., Sue L., Wong P., Price D., Li R., and Shen Y. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat. Med. 9 (2003) 3-4
118. Yu H., Saura C.A., Choi S.Y., Sun L.D., Yang X., Handler M., Kawarabayashi T., Younkin L., Fedeles B., Wilson M.A., Younkin S., Kandel E.R., Kirkwood A., and Shen J. APP processing and synaptic plasticity in presenilin-1 conditional knockout mice. Neuron 31 (2001) 713-726
119. Zhang X., Zhou K., Wang R., Cui J., Lipton S.A., Liao F.F., Xu H., and Zhang Y.W. Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J. Biol. Chem. 282 (2007) 10873-10880
120. Zhao J., Fu Y., Yasvoina M., Shao P., Hitt B., O'Connor T., Logan S., Maus E., Citron M., Berry R., Binder L., and Vassar R. Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. J. Neurosci. 27 (2007) 3639-3649